STOCK TITAN
  1. Home
  2. Sec-filings
  3. SOPH
  4. [Form 4/A] SOPHiA GENETICS SA Amended Insider Trading Activity

[Form 4/A] SOPHiA GENETICS SA Amended Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

CARDOZA GEORGE reported acquisition or exercise transactions in this Form 4 filing.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza received new equity awards and corrected a prior ownership figure. On April 2, 2026 he was granted options to buy 164,671 ordinary shares at $5.04 per share, vesting 25% on April 2, 2027 and then monthly through April 2, 2030. He also received 112,936 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. After these awards, he beneficially owns 297,794 ordinary shares directly, correcting a previously reported amount of 112,936 shares that was described as an inadvertent error.

Positive

  • None.

Negative

  • None.

Insights

CFO receives time-based equity grants and corrects share count.

The filing shows compensation-related equity awards to SOPHiA GENETICS SA’s CFO, not open-market buying or selling. He received 164,671 options at an exercise price of $5.04 plus 112,936 RSUs, all contingent on continued service.

Both the options and RSUs vest over several years, with 25% vesting on April 2, 2027 and the remainder through April 2, 2030. This structure is typical for retention and alignment, linking his upside to the company’s long-term performance.

The amendment primarily corrects the post-transaction ownership figure to 297,794 ordinary shares, previously misreported as 112,936. There is no sale, tax withholding, or 10b5-1 activity disclosed here, so the filing is largely administrative from a market-signal perspective.

Insider CARDOZA GEORGE
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Share Option (Right to Buy) 164,671 $0.00 --
Grant/Award Ordinary Shares 112,936 $0.00 --
Holdings After Transaction: Share Option (Right to Buy) — 164,671 shares (Direct); Ordinary Shares — 297,794 shares (Direct)
Footnotes (1)
  1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 297,794 ordinary shares. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CARDOZA GEORGE
(Last)(First)(Middle)
C/O SOPHIA GENETICS INC.
401 PARK DRIVE, FLOOR 5
(Street)
BOSTON MASSACHUSETTS 02215
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
04/03/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/02/2026A112,936(1)A$0297,794(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$5.0404/02/2026A164,671 (3)04/02/2036Ordinary Shares164,671$0164,671D
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 297,794 ordinary shares.
3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Remarks:
/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza04/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did SOPHiA GENETICS (SOPH) CFO George Cardoza acquire in this Form 4/A?

He received equity awards as compensation, not market purchases. The grants include 164,671 options to buy ordinary shares at $5.04 per share and 112,936 restricted stock units, all subject to continued service and multi-year vesting schedules ending in 2030.

How do the SOPH CFO’s new RSUs vest according to this Form 4/A?

The 112,936 RSUs vest over four years. 25% vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on George Cardoza’s continued service with SOPHiA GENETICS SA.

What is the vesting schedule for the SOPH CFO’s new share options?

The 164,671 options vest in stages. 25% of the underlying ordinary shares vest on April 2, 2027, then the remaining portion vests in equal monthly installments through April 2, 2030, aligning long-term incentives with ongoing employment at SOPHiA GENETICS SA.

What ownership correction does this SOPHiA GENETICS (SOPH) Form 4/A disclose?

It corrects the reported post-transaction share count. The prior Form 4 listed 112,936 ordinary shares beneficially owned after the transaction. The amended filing states the correct amount is 297,794 ordinary shares directly owned by CFO George Cardoza.

Does this SOPH Form 4/A show any insider stock sales by the CFO?

No sales are reported. The transactions are coded as A, indicating grants or awards of options and RSUs at a price of $0.00 per share. There are no open-market purchases, sales, gifts, or tax-withholding dispositions disclosed in this amendment.

What is the exercise price and expiration date of the SOPH CFO’s new options?

The options have an exercise price of $5.04 per ordinary share and an expiration date of April 2, 2036. They become exercisable as they vest, beginning on April 2, 2027, and continuing through April 2, 2030, assuming continued employment.